BG Medicine's Q3 Revenues Shoot up 83 Percent, Plans FDA Submissions | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine today reported an 83 percent jump year over year in third-quarter revenues and progress in its plans to file for regulatory approval of its tests.

The Waltham, Mass.-based company posted $179,000 in revenues for the three months ended Sept. 30, up from $98,000 a year ago, which it attributed to an increase in sales of its galectin-3 test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.